Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study

I. Pearce, S. Banerjee, B.J.L. Burton, U. Chakravarthy, L. Downey, R.P. Gale, J. Gibson, S. Pagliarini, J. Patel, S. Sivaprasad, C. Andrews, C. Brittain, J. Warburton

Research output: Contribution to journal › Article › peer-review

44 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science